145 documents found, page 1 of 15
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0...
Espay, Alberto J; Stocchi, Fabrizio; Pahwa, Rajesh; Albanese, Alberto; Ellenbogen, Aaron; Ferreira, Joaquim J; Giladi, Nir; Gurevich, TanyaBackground: Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-re...
Factors associated with self-rated health in people with late-stage parkinson’s...
Pigott, Jennifer S.; Armstrong, Megan; Davies, Nathan; Davis, Daniel; Bloem, Bastiaan R.; Lorenzl, Stefan; Meissner, Wassilios G.; Odin, PerPurpose: To investigate the contributors to self-rated health in people with late-stage Parkinson's disease (PD) and cognitive impairment. Methods: A secondary analysis of baseline data from the international Care of Late-Stage Parkinsonism (CLaSP) cohort study was conducted. Participants with PD and either dementia or mild cognitive impairment or MMSE < 24/30 in the absence of major depression were included if...
Association of body mass index and Parkinson disease
Domenighetti, Cloé; Sugier, Pierre-Emmanuel; Ashok Kumar Sreelatha, Ashwin; Schulte, Claudia; Grover, Sandeep; Portugal, Berta; Lee, Pei-ChenBackground and objectives: The role of body mass index (BMI) in Parkinson disease (PD) is unclear. Based on the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in PD (Courage-PD) consortium, we used 2-sample Mendelian randomization (MR) to replicate a previously reported inverse association of genetically predicted BMI with PD and investigated whether findings were robust in analyses ...
Immune-related serious adverse events with immune checkpoint inhibitors: system...
Oliveira, Clara; Mainoli, Beatrice; Duarte, Gonçalo Silva; Machado, Tiago; Tinoco, Rita G.; Esperança Martins, Miguel; Ferreira, Joaquim J; Costa, JoãoPurpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, though uncertainty exists regarding their immune-related safety. The objective of this study was to assess the comparative safety profile (odds ratio) of ICIs and estimate the absolute rate of immune-related serious adverse events (irSAEs) in cancer patients undergoing treatment with ICIs. Methods: We searched for randomized tria...
Opicapone to treat early wearing‐off in Parkinson's disease patients: the korea...
Lee, Jee‐Young; Ma, Hyeo‐il; Ferreira, Joaquim J; Rocha, José Francisco; Sung, Young Hee; Song, In‐Uk; Ahn, Tae‐Beom; Kwon, Do Young; Cheon, Sang‐MyungBackground: Increasing levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol-O-methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing-off symptoms in Parkinson's disease (PD) patients. Objectives: To evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing-off in PD patients. Methods: ADOPTION wa...
Embracing monogenic Parkinson's disease: the MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane; Schaake, Susen; Lohmann, Katja; Padmanabhan, Shalini; Brice, Alexis; Lesage, Suzanne; Tesson, Christelle; Vidailhet, MarieBackground: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. Objectiv...
Atrial fibrillation risk on Parkinson’s disease: a systematic review and meta-a...
Cereja, Fátima; Alves, Mariana; Ferreira, Joaquim J; Caldeira, DanielThe association of Parkinson's Disease (PD) with atrial fibrillation (AF) is not well established and previous studies' results were heterogeneous. This review aimed to evaluate if patients with PD are at increased risk of having AF. MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science, were searched from inception May 2021. Two reviewers independently selected observational stu...
Confusion of evidence‐based reviews and guidelines
Deuschl, Günther; Antonini, Angelo; Costa, João; Śmiłowska, Katarzyna; Berg, Daniela; Corvol, Jean‐Christophe; Fabbrini, Giovanni; Ferreira, Joaquim JHariz and colleagues [1] argue that the new EAN/MDS GL contradicts the repeated endorsements of pallidotomy by the MDS. The MDS has previously published “evidence based medicine (EBM) reviews,” which appraise each treatment on the basis of welldefined criteria but are not GLs. Clinical GLs, such as the new EAN/MDS GL, also take into consideration other variables, including context, summarizing the current medic...
Optimizing levodopa therapy, when and how? Perspectives on the importance of de...
Lees, Andrew; Tolosa, Eduardo; Stocchi, Fabrizio; Ferreira, Joaquim J; Rascol, Olivier; Antonini, Angelo; Poewe, WernerIntroduction: There is currently a resurgence of levodopa as the initial treatment of choice for most patients with Parkinson's disease, albeit at lower doses than previously used. The addition of adjuvant treatments (including MAO-B inhibitors, COMT inhibitors and dopamine agonists) is an established strategy to reduce motor complications that develop with sustained levodopa therapy. Areas covered: In this nar...
Meaning in life in late-stage Parkinson’s disease: results from the care of lat...
Bublitz, Sarah K.; Brandstötter, Cornelia; Fegg, Martin; Ferreira, Joaquim J; Odin, Per; Bloem, Bastiaan R.; Meissner, Wassilios G.; Dodel, RichardThe Care of Late-Stage Parkinsonism (CLaSP) study is a longitudinal, multicentre, prospective cohort study to assess the needs and provision of care for people with late-stage Parkinson's disease and their caregivers in six European countries. As a cross-sectional study within the CLaSP study, 509 people with Parkinson's disease completed the "Schedule-for-Meaning-in-Life-Evaluation" (SMiLE) questionnaire. We c...